Daprodustat - GlaxoSmithKline

Drug Profile

Daprodustat - GlaxoSmithKline

Alternative Names: 1278863; GSK-1278863; GSK-1278863A

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics; Antianaemics; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Phase II Perioperative ischaemia
  • No development reported Diabetic foot ulcer; Tendon injuries
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 31 Oct 2018 Phase III trial meets its primary endpoint in patients with Anaemia associated with Chronic kidney disease
  • 29 Oct 2018 GlaxoSmithKline plans regulatory submission to the Japanese Ministry of Health, Labour and Welfare (JMHLW) for Anaemia in 2019
  • 29 Oct 2018 Efficacy and adverse events data from a phase III trial in Anaemia released by GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top